Amorfix achieves technical milestone in development of a blood test for Alzheimer's disease


Amorfix Life Sciences Inc. and the Ontario Genomics Institute (OGI) announced the achievement of the technical milestone of demonstrating that Amorfix's Epitope Protection (EP) technology is able to detect protected sites within Abeta amyloid aggregates which are formed in Alzheimer's disease. With this advancement, Amorfix will be committing additional resources to develop an ultra-sensitive blood test for Alzheimer's disease, EP-AD(TM), based upon Amorfix's patent-pending EP technology.

Pursuant to the subscription agreement executed January 30, 2006, OGI will now invest its second tranche of $50,000 in Amorfix. This transaction is subject to acceptance for filing by the TSX Venture Exchange.

Other news from the department research and development

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics